Defective entities and uses therefor by Cornford-Nairn, Renee et al.
 IP Australia 
DEFECTIVE ENTITIES AND USES THEREFOR - AU2002357406 
ABSTRACT & PATENT DETAILS  
Inventor/s:  
 Cornford-Nairn, Renee  
 Daggard, Grant Edward  
 Mukkur, Trilochan Kanwaljit Singh  
 Rossetti, Tony Robert  
Assignee/s:  
 Trilochan Kanwaljit Singh Mukkur  
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) 
World Intellectual Property Organization International Bureau (43) International Publication Date 24 July 2003 
(24.07.2003) 0~ 1111111111111 11 111111111111111111111111111111111111 1111111111 
11111111111111111111111111111111 (10) International Publication Number WO 03/060105 Al PCT (51) 
International Patent Classification 7 CI2N 1/20 (74) Agents: ARGAET, Victor, Peter et al.; Davies Collison Cave, 
Level 3, 303 Coronation Drive, Milton, Queensland (21) International Application Number: PCT/AU02/01768 4064 
(AU). (22) International Filing Date: December 2002 (30.1 Filing Language: (26) Publication Language: (81) 
Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, 
2.2002) CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, IIR, IIU, ID, IL, IN, IS, JP, KE, KG, KP, KR, 
KZ, LC, English LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, 
RU, SC, SD, SE, English SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW. 
Priority Data: PR 9776 28 December 2001 (28.12.2001) AU (71) Applicant (for all designated States except US): 
DELTA BIOTECHNOLOGY LIMITED [AU/AU]; McCullough Robertson, Level 12, Central Plaza 2, 66 Eagle 
Street, Brisbane, Queensland 4000 (AU). (72) Inventors; and Inventors/Applicants (for US only): CORN- FORD-
NAIRN, Renee [AU/AU]; 74 Iron Bark Drive, Mt Rascal, Queensland 4350 DAGGARD, Grant, Edward [AU/AU]; 
151 Long Street, Toowoomba, Queens- land 4350 MUKKUR, Trilochan, Kanwaljit, Singh [AU/AU]; 31 Ocean 
Street, Toowoomba, Queensland 4350 ROSSETTI, Tony, Robert [AU/AU]; Unit 3, 24 Lima Street, Auchenflower, 
Queensland 4066 (AU). (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, 
SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, 
CH, CY CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, 
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: -with international search report -before 
the expiration of the time limit for amending the claims and to be republished in the event of receipt of 
amendments For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and 
Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette. (54) Title: DEFECTIVE 
ENTITIES AND USES THEREFOR (57) Abstract: The present invention discloses the structure and sequence 
ofaroQ from Bordetella pertussis, which are useful inter alia for the production of the genetically modified 
attenuated Bordetella strains of the present invention and for detecting and isolating variant aroQ genes and 
expression products. The present invention also discloses attenuated Bordetella strains of pathogenic origin, and 
more particularly genetically modified Bordetella strains, which have been attenuated by disruption or inactivation 
of the aroQ gene. The genetically modified Bordetella strain of the present invention has a reduced capacity to 
propagate in a mammalian host, but remains viable in the host for a period of time sufficient to induce a 
protective immune response against the natural pathogenic Bordetella counterpart. The present invention is also 
directed to the use of such genetically modified Bordetella strains in immunopotentiating compositions for treating 
and/or preventing inter alia Bordetella infections, and particularly pathogenic infections, caused by Bordetella. 
This page contains all relevant details related to patent number AU2002357406. This patent was filed on 
30/12/2002 and has a status of GRANTED. The inventors associated with this patent are:  
 Cornford-Nairn, Renee  
 Daggard, Grant Edward  
 Mukkur, Trilochan Kanwaljit Singh  
 Rossetti, Tony Robert  
The applicant/owner of the patent is registered as Trilochan Kanwaljit Singh Mukkur. They used the patent 
attorney firm Fisher Adams Kelly Pty Ltd to file this.  
Australian patent AU2002357406 is one of over a million that we feature on IP in Australia which covers the 
entire spectrum of patents in Australia. Trilochan Kanwaljit Singh Mukkur is also one of thousands of applicants 
we’ve analysed. We also understand who are the most prolific inventors in Australia with details on all the patents 
attributed to individuals.  
Because we have insights into all the attorney firms that have been used across Australia including which specific 
patent attorney worked on each patent, we have access to unique analytics on the best attorney to use if you 
have specific patent needs i.e. it would make sense that the patent attorney you should use for your invention is 
the one who is most active and has the most experience in your technology area.  
Filing patents is a time consuming and expensive exercise which is why care needs to be taken ensuring that 
you’re working with the right individual.  
Because we’re an independent third party we can give you unbiased insights and recommendations on the right 
partner to choose. For more information contact us 
PUBLICATIONS  
Vol/Iss Pub. Date Publication Action Reason 
22/42 23/10/2008 Letters Patent Sealed - Standard Patents 
 
22/25 26/06/2008 Applications Accepted 
 
22/18 08/05/2008 Assignments Before Grant, Section 113 
 
17/35 04/09/2003 Applications OPI 
 
17/13 27/03/2003 Complete Applications Filed 
 




CLAIMS 1. A genetically modified Bordetella strain having a partial or complete loss of 00 function in the 
endogenous aroQ gene and a lower capacity to propagate in a mammalian host but remaining viable in the host 
for a period of time sufficient to NO induce an immune response against a pathogenic Bordetella strain. 2. The 
genetically modified strain of claim 1, wherein the pathogenic Bordetella strain is a natural counterpart of the 
genetically modified Bordetella strain, or is a 0 10 related pathogenic Bordetella organism. 3. The genetically 
modified strain of claim 1, wherein the pathogenic strain is selected from Bordetella avium, Bordetella 
bronchiseptica, Bordetella holmesii, Bordetella parapertussis and Bordetella pertussis. 4. The genetically 
modified strain of claim 1, wherein the pathogenic Bordetella strain is Bordetella pertussis. The genetically 
modified strain of claim 1, comprising a disruption in the endogenous aroQ gene. 6. The genetically modified 
strain of claim 5, wherein the disruption has been introduced into the genome of a pathogenic strain of Bordetella 
by homologous recombination with a DNA targeting construct such that the targeting construct is stably 
integrated in the genome, wherein the disruption of the aroQ gene results in a reduced level and/or functional 
activity of the 3-dehydroquinase. 7. The genetically modified strain of claim 5, comprising an exogenous nucleic 
acid sequence in its genome, or on an extrachromosomal element, which is capable of abolishing or otherwise 
reducing the expression of aroQ or the level and/or functional activity of the 3-dehydroquinase encoded by aroQ.-
76- 00 8. The genetically modified strain of claim 5, comprising an exogenous nucleic N acid sequence in its 
genome, or on an extrachromosomal element, which is capable of abolishing or otherwise reducing the 
expression of aroQ or the level and/or functional 00 activity of the 3-dehydroquinase encoded by aroQ, wherein 
the nucleic acid sequence comprises at lest a portion of aroQ, in the sense or anti-sense orientation, which is IND 
operably linked to a transcriptional control element. 9. The genetically modified strain of claim 1, further having a 
partial or complete C loss of function in at least one other endogenous gene selected from a purgene, 0 10 
another aro gene, a pertussis toxin gene, or any other gene which contributes to survival in the host and/or to 
bacterial virulence, or a combination thereof. The genetically modified Bordetella strain of claim 1, comprising at 
least one exogenous gene which is capable for expressing an antigen that is heterologous or foreign to the 
Bordetella strain. 11. The genetically modified Bordetella strain of claim 10, wherein the heterologous or foreign 
antigen is derived from a pathogen that is unrelated to the Bordetella strain. 12. The genetically modified 
Bordetella strain of claim 10, wherein the heterologous or foreign antigen is derived from a pathogen that infects 
by the mucosal route. 13. An isolated polynucleotide comprising a nucleotide sequence set forth in SEQ ID NO: 1 
or 3, or is complementary to the sequence set forth in SEQ ID NO: 1 or 3. 14. An isolated polynucleotide 
comprising a nucleotide sequence having at least sequence identity to at least a portion of the sequence set forth 
in SEQ ID NO: 1 or 3, wherein said portion is at least 150 nucleotides in length.-77- 00 The isolated 
polynucleotide of claim 14 wherein the nucleotide sequence has at least 90% sequence identity at least a portion 
of the sequence set forth in SEQ ID SNO: 1 or 3, wherein said portion is at least 150 nucleotides in length. 00 16. 
A nucleic acid construct for disrupting an aroQ gene in a Bordetella cell, N comprising: a) a non-homologous 
replacement portion; b) a first homology region located upstream of the non-homologous replacement portion, 
the first homology region having a nucleotide sequence with substantial identity to a first aroQ gene sequence; 
and c) a second homology region located downstream of the non- homologous replacement portion, the second 
homology region having a nucleotide sequence with substantial identity to a second aroQ gene sequence, the 
second aroQ gene sequence having a location downstream of the first aroQ gene sequence in a naturally 
occurring endogenous aroQ gene of the Bordetella cell. 17. The construct of claim 16, wherein the aroQ gene 
comprises the isolated polynucleotide as set forth in any one of claims 13 to 18. A vector comprising a nucleotide 
sequence that corresponds or is complementary to the isolated polynucleotide sequence as set forth in any one 
of claims 13 to 19. The vector of claim 18, wherein the vector is a DNA targeting vector. A host cell containing the 
construct of claim 16 or claim 17 or the vector of claim 18 or claim 19. 21. A method for producing a genetically 
modified Bordetella strain, comprising introducing the nucleic acid construct of claim 25 into a Bordetella cell 
under conditions such that the nucleic acid construct is homologously recombined into the aroQ gene in the 
genome of that cell to produce a genetically modified Bordetella cell containing a disrupted aroQ gene.-78- 00 22. 
The method of claim 21, wherein the genetically modified Bordetella cell containing the homologously 
recombined nucleic acid construct is further characterised by expressing reduced or undetectable levels of aroQ. 
00 23. The method of claim 21, wherein the genetically modified Bordetella cell N lacks the ability to produce a 
functional 3-dehydroquinase encoded by said aroQ gene. 24. A composition, comprising the genetically modified 
Bordetella strain of claim C 10 1, together with a pharmaceutically acceptable carrier. The composition of claim 
24, further comprising an adjuvant. 26. A composition of matter comprising dendritic cells which have been 
exposed to the genetically modified Bordetella strain of claim 1 for a time and under conditions sufficient to 
express a processed or modified antigen derived from the Bordetella strain for presentation to, and modulation of, 
T cells. 27. The composition of matter of claim 26, which is in the form of an in vitro cell culture. 28. A method for 
modulating an immune response, comprising administering to a patient in need of such treatment an effective 
amount of the genetically modified Bordetella strain of claim 1, or the composition of any one of claims 22-25 or 
the composition of matter of claim 26. 29. A method for the treatment and/or prophylaxis of whooping cough or 
related condition, comprising administering to a patient in need of such treatment an effective amount of the 
genetically modified Bordetella strain of claim 1, or the composition of any one of claims 22-25 or the composition 
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